| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Suicide, Attempted | 27 | 2025 | 140 | 7.660 |
Why?
|
| Suicide | 25 | 2023 | 162 | 7.060 |
Why?
|
| Diagnosis, Computer-Assisted | 20 | 2024 | 337 | 6.200 |
Why?
|
| Bipolar Disorder | 22 | 2024 | 399 | 5.280 |
Why?
|
| Depressive Disorder | 40 | 2019 | 225 | 4.870 |
Why?
|
| Dengue | 37 | 2019 | 51 | 4.460 |
Why?
|
| Mental Disorders | 31 | 2025 | 455 | 4.420 |
Why?
|
| Psychotic Disorders | 13 | 2025 | 230 | 4.080 |
Why?
|
| Depressive Disorder, Major | 15 | 2022 | 171 | 4.010 |
Why?
|
| Substance-Related Disorders | 14 | 2025 | 441 | 3.640 |
Why?
|
| Dengue Virus | 33 | 2019 | 49 | 3.530 |
Why?
|
| Psychiatric Status Rating Scales | 33 | 2024 | 502 | 3.440 |
Why?
|
| Self-Injurious Behavior | 6 | 2023 | 114 | 3.200 |
Why?
|
| Depression | 21 | 2025 | 544 | 3.140 |
Why?
|
| Randomized Controlled Trials as Topic | 21 | 2023 | 920 | 3.040 |
Why?
|
| Psychometrics | 18 | 2022 | 337 | 2.690 |
Why?
|
| Schizophrenia | 21 | 2025 | 529 | 2.620 |
Why?
|
| Adolescent | 113 | 2025 | 9606 | 2.590 |
Why?
|
| Anxiety | 12 | 2025 | 337 | 2.480 |
Why?
|
| Suicidal Ideation | 11 | 2025 | 75 | 2.330 |
Why?
|
| Humans | 312 | 2025 | 93515 | 2.220 |
Why?
|
| Anxiety Disorders | 9 | 2022 | 155 | 2.210 |
Why?
|
| Male | 186 | 2025 | 44557 | 1.890 |
Why?
|
| Adult | 127 | 2025 | 27918 | 1.850 |
Why?
|
| Female | 186 | 2025 | 48702 | 1.830 |
Why?
|
| Antidepressive Agents | 14 | 2021 | 109 | 1.800 |
Why?
|
| Child | 88 | 2025 | 7355 | 1.740 |
Why?
|
| Veterans | 5 | 2022 | 99 | 1.690 |
Why?
|
| Antibodies, Viral | 25 | 2019 | 322 | 1.600 |
Why?
|
| Fluoxetine | 5 | 2015 | 41 | 1.580 |
Why?
|
| Personality Inventory | 9 | 2014 | 111 | 1.580 |
Why?
|
| United States | 63 | 2025 | 7622 | 1.580 |
Why?
|
| Child of Impaired Parents | 2 | 2025 | 18 | 1.530 |
Why?
|
| Cyclohexanols | 4 | 2013 | 7 | 1.510 |
Why?
|
| Models, Statistical | 18 | 2017 | 585 | 1.480 |
Why?
|
| Mass Screening | 9 | 2025 | 696 | 1.480 |
Why?
|
| Longitudinal Studies | 26 | 2022 | 1161 | 1.460 |
Why?
|
| Young Adult | 49 | 2025 | 6930 | 1.450 |
Why?
|
| Analgesics, Opioid | 8 | 2022 | 513 | 1.380 |
Why?
|
| Parents | 3 | 2025 | 292 | 1.370 |
Why?
|
| Thailand | 41 | 2019 | 66 | 1.290 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 12 | 2019 | 184 | 1.280 |
Why?
|
| Middle Aged | 91 | 2025 | 27573 | 1.260 |
Why?
|
| Influenza, Human | 13 | 2018 | 347 | 1.230 |
Why?
|
| Reproducibility of Results | 19 | 2024 | 2715 | 1.230 |
Why?
|
| Anticonvulsants | 4 | 2010 | 127 | 1.200 |
Why?
|
| Models, Psychological | 8 | 2022 | 164 | 1.190 |
Why?
|
| Regression Analysis | 21 | 2017 | 579 | 1.140 |
Why?
|
| Drug Prescriptions | 10 | 2019 | 150 | 1.140 |
Why?
|
| Emergency Service, Hospital | 7 | 2025 | 579 | 1.120 |
Why?
|
| Antipsychotic Agents | 6 | 2024 | 146 | 1.100 |
Why?
|
| Research Design | 16 | 2022 | 617 | 1.090 |
Why?
|
| Sexual and Gender Minorities | 2 | 2021 | 250 | 1.040 |
Why?
|
| Tissue and Organ Procurement | 7 | 2025 | 388 | 1.020 |
Why?
|
| Central Nervous System Stimulants | 9 | 2019 | 233 | 0.990 |
Why?
|
| Severe Dengue | 9 | 2016 | 9 | 0.990 |
Why?
|
| Risk Factors | 30 | 2025 | 5899 | 0.980 |
Why?
|
| Data Interpretation, Statistical | 7 | 2017 | 306 | 0.980 |
Why?
|
| Cluster Analysis | 18 | 2022 | 391 | 0.980 |
Why?
|
| Observational Studies as Topic | 3 | 2023 | 55 | 0.920 |
Why?
|
| Child, Preschool | 48 | 2019 | 3829 | 0.890 |
Why?
|
| Lithium Compounds | 2 | 2018 | 10 | 0.870 |
Why?
|
| Population Surveillance | 6 | 2015 | 213 | 0.870 |
Why?
|
| Drug Overdose | 3 | 2022 | 89 | 0.860 |
Why?
|
| Alprazolam | 1 | 2024 | 4 | 0.830 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 7 | 2018 | 112 | 0.830 |
Why?
|
| Anti-Anxiety Agents | 1 | 2024 | 23 | 0.830 |
Why?
|
| Outpatients | 4 | 2021 | 104 | 0.800 |
Why?
|
| Cohort Studies | 27 | 2023 | 3054 | 0.800 |
Why?
|
| Psychological Tests | 3 | 2014 | 88 | 0.800 |
Why?
|
| Risk Assessment | 12 | 2024 | 2441 | 0.790 |
Why?
|
| Cannabis | 1 | 2024 | 38 | 0.790 |
Why?
|
| Heart Transplantation | 6 | 2025 | 811 | 0.790 |
Why?
|
| Evidence-Based Practice | 5 | 2016 | 51 | 0.790 |
Why?
|
| Computer Simulation | 5 | 2020 | 1118 | 0.770 |
Why?
|
| Aged | 50 | 2025 | 20434 | 0.770 |
Why?
|
| High Pressure Neurological Syndrome | 1 | 2022 | 1 | 0.760 |
Why?
|
| Meta-Analysis as Topic | 5 | 2015 | 83 | 0.760 |
Why?
|
| Environmental Restoration and Remediation | 1 | 2022 | 8 | 0.760 |
Why?
|
| Encephalitis, Japanese | 6 | 2015 | 6 | 0.750 |
Why?
|
| Vitamin D Deficiency | 1 | 2022 | 107 | 0.700 |
Why?
|
| Mental Health | 3 | 2019 | 188 | 0.680 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2021 | 125 | 0.670 |
Why?
|
| Treatment Outcome | 27 | 2023 | 9099 | 0.670 |
Why?
|
| Waiting Lists | 5 | 2025 | 210 | 0.640 |
Why?
|
| Sample Size | 2 | 2013 | 128 | 0.630 |
Why?
|
| Adolescent Behavior | 2 | 2019 | 111 | 0.620 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2015 | 20 | 0.620 |
Why?
|
| Infant | 30 | 2023 | 3220 | 0.600 |
Why?
|
| Pressure Ulcer | 2 | 2017 | 44 | 0.590 |
Why?
|
| Cross-Sectional Studies | 14 | 2019 | 1847 | 0.590 |
Why?
|
| Child Behavior | 1 | 2019 | 45 | 0.590 |
Why?
|
| Encephalitis Virus, Japanese | 5 | 2015 | 6 | 0.590 |
Why?
|
| Neocortex | 1 | 2020 | 98 | 0.580 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2015 | 202 | 0.580 |
Why?
|
| Prisoners | 1 | 2019 | 47 | 0.580 |
Why?
|
| Lung Transplantation | 3 | 2016 | 367 | 0.560 |
Why?
|
| Hospitals, Psychiatric | 4 | 2017 | 25 | 0.560 |
Why?
|
| Psychotherapy | 6 | 2023 | 72 | 0.560 |
Why?
|
| Surveys and Questionnaires | 10 | 2021 | 2802 | 0.560 |
Why?
|
| Transients and Migrants | 1 | 2018 | 6 | 0.560 |
Why?
|
| Groundwater | 1 | 2018 | 14 | 0.550 |
Why?
|
| Poisson Distribution | 4 | 2014 | 47 | 0.540 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2017 | 6 | 0.530 |
Why?
|
| Hospitals, General | 1 | 2017 | 11 | 0.530 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 46 | 0.530 |
Why?
|
| Hospital Bed Capacity | 1 | 2017 | 20 | 0.530 |
Why?
|
| Prevalence | 12 | 2025 | 1321 | 0.520 |
Why?
|
| Dengue Vaccines | 6 | 2019 | 6 | 0.520 |
Why?
|
| Severity of Illness Index | 15 | 2019 | 1917 | 0.520 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 3 | 2018 | 87 | 0.520 |
Why?
|
| Retrospective Studies | 23 | 2025 | 10164 | 0.510 |
Why?
|
| Hospitalization | 13 | 2020 | 937 | 0.500 |
Why?
|
| Logistic Models | 15 | 2017 | 1243 | 0.490 |
Why?
|
| Prospective Studies | 26 | 2023 | 4560 | 0.490 |
Why?
|
| Deep Brain Stimulation | 1 | 2017 | 89 | 0.480 |
Why?
|
| Smoking Cessation | 4 | 2017 | 269 | 0.480 |
Why?
|
| Cancer Survivors | 1 | 2017 | 88 | 0.480 |
Why?
|
| Dementia | 1 | 2018 | 214 | 0.480 |
Why?
|
| Reoperation | 3 | 2009 | 702 | 0.470 |
Why?
|
| Incidence | 15 | 2018 | 1701 | 0.470 |
Why?
|
| Military Personnel | 6 | 2022 | 104 | 0.470 |
Why?
|
| Statistics as Topic | 10 | 2017 | 228 | 0.470 |
Why?
|
| Sensitivity and Specificity | 16 | 2021 | 1922 | 0.460 |
Why?
|
| Antibodies, Neutralizing | 6 | 2015 | 162 | 0.460 |
Why?
|
| Behavior Therapy | 7 | 2013 | 93 | 0.460 |
Why?
|
| RNA, Viral | 10 | 2018 | 285 | 0.450 |
Why?
|
| Tissue Donors | 3 | 2016 | 541 | 0.440 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 3 | 2011 | 22 | 0.440 |
Why?
|
| Leukotriene Antagonists | 2 | 2012 | 24 | 0.440 |
Why?
|
| Prescriptions | 4 | 2022 | 26 | 0.440 |
Why?
|
| Biometry | 5 | 2007 | 70 | 0.430 |
Why?
|
| Waste Management | 1 | 2014 | 4 | 0.430 |
Why?
|
| Water Pollution, Chemical | 1 | 2014 | 21 | 0.420 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 394 | 0.420 |
Why?
|
| Bartonella Infections | 2 | 2011 | 5 | 0.420 |
Why?
|
| Bartonella | 2 | 2011 | 6 | 0.420 |
Why?
|
| Time Factors | 20 | 2020 | 5410 | 0.420 |
Why?
|
| Sentinel Surveillance | 2 | 2018 | 23 | 0.410 |
Why?
|
| Social Control Policies | 1 | 2013 | 2 | 0.410 |
Why?
|
| Rabies | 2 | 2004 | 6 | 0.410 |
Why?
|
| Quinoxalines | 1 | 2013 | 51 | 0.400 |
Why?
|
| Benzazepines | 1 | 2013 | 65 | 0.400 |
Why?
|
| Opioid-Related Disorders | 4 | 2022 | 233 | 0.390 |
Why?
|
| Heart Rate | 2 | 2014 | 505 | 0.390 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 442 | 0.390 |
Why?
|
| Autistic Disorder | 1 | 2014 | 150 | 0.380 |
Why?
|
| Antigens, Viral | 5 | 2015 | 122 | 0.380 |
Why?
|
| Odds Ratio | 9 | 2020 | 711 | 0.380 |
Why?
|
| Water Pollutants, Chemical | 1 | 2014 | 140 | 0.380 |
Why?
|
| Intellectual Disability | 1 | 2014 | 195 | 0.380 |
Why?
|
| Benzodiazepines | 2 | 2024 | 56 | 0.380 |
Why?
|
| Aged, 80 and over | 16 | 2018 | 7061 | 0.370 |
Why?
|
| Psychiatry | 3 | 2011 | 86 | 0.370 |
Why?
|
| Primary Health Care | 6 | 2023 | 378 | 0.370 |
Why?
|
| Biostatistics | 1 | 2012 | 21 | 0.360 |
Why?
|
| Firearms | 1 | 2013 | 79 | 0.360 |
Why?
|
| Mood Disorders | 9 | 2017 | 82 | 0.360 |
Why?
|
| Comorbidity | 6 | 2024 | 1007 | 0.360 |
Why?
|
| Tachycardia | 1 | 2012 | 38 | 0.360 |
Why?
|
| Quality Improvement | 1 | 2016 | 485 | 0.360 |
Why?
|
| Decision Making | 2 | 2016 | 674 | 0.350 |
Why?
|
| Immunoglobulin M | 3 | 2012 | 153 | 0.350 |
Why?
|
| Liver Transplantation | 4 | 2004 | 1194 | 0.350 |
Why?
|
| Heart-Assist Devices | 2 | 2010 | 882 | 0.340 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2025 | 3476 | 0.340 |
Why?
|
| Databases, Factual | 7 | 2020 | 1006 | 0.340 |
Why?
|
| Asymptomatic Infections | 5 | 2015 | 19 | 0.340 |
Why?
|
| Bayes Theorem | 5 | 2023 | 402 | 0.330 |
Why?
|
| Pandemics | 5 | 2022 | 873 | 0.330 |
Why?
|
| Feedback, Psychological | 1 | 2011 | 20 | 0.330 |
Why?
|
| Follow-Up Studies | 21 | 2021 | 3830 | 0.330 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2010 | 17 | 0.330 |
Why?
|
| Respiratory Tract Infections | 3 | 2018 | 110 | 0.330 |
Why?
|
| Amines | 1 | 2010 | 31 | 0.330 |
Why?
|
| Prescription Drugs | 3 | 2025 | 38 | 0.330 |
Why?
|
| United States Food and Drug Administration | 6 | 2012 | 142 | 0.320 |
Why?
|
| Multicenter Studies as Topic | 4 | 2007 | 181 | 0.320 |
Why?
|
| Electronic Health Records | 4 | 2022 | 372 | 0.320 |
Why?
|
| Quality of Life | 2 | 2022 | 1780 | 0.320 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2010 | 86 | 0.320 |
Why?
|
| Cause of Death | 2 | 2009 | 273 | 0.320 |
Why?
|
| Spain | 3 | 2020 | 33 | 0.310 |
Why?
|
| Psychology, Clinical | 1 | 2010 | 7 | 0.310 |
Why?
|
| Vaccination | 7 | 2022 | 304 | 0.310 |
Why?
|
| Age Factors | 13 | 2014 | 1906 | 0.310 |
Why?
|
| Drug Approval | 2 | 2010 | 68 | 0.300 |
Why?
|
| Brain | 4 | 2025 | 2391 | 0.300 |
Why?
|
| Biomedical Research | 1 | 2014 | 438 | 0.300 |
Why?
|
| Health Care Rationing | 2 | 2016 | 83 | 0.300 |
Why?
|
| Empathy | 1 | 2011 | 150 | 0.290 |
Why?
|
| Blood Pressure | 2 | 2016 | 896 | 0.290 |
Why?
|
| Insurance, Health | 5 | 2025 | 179 | 0.290 |
Why?
|
| Accidents, Traffic | 2 | 2022 | 102 | 0.290 |
Why?
|
| Demography | 1 | 2009 | 189 | 0.290 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2008 | 37 | 0.290 |
Why?
|
| Heart-Lung Transplantation | 1 | 2008 | 20 | 0.280 |
Why?
|
| Models, Theoretical | 4 | 2009 | 494 | 0.280 |
Why?
|
| Prosthesis-Related Infections | 1 | 2009 | 61 | 0.280 |
Why?
|
| Predictive Value of Tests | 6 | 2024 | 1713 | 0.280 |
Why?
|
| Hepatitis E virus | 3 | 2013 | 5 | 0.280 |
Why?
|
| Hepatitis E | 3 | 2013 | 5 | 0.280 |
Why?
|
| Mammals | 1 | 2010 | 259 | 0.280 |
Why?
|
| Genetic Variation | 3 | 2014 | 1415 | 0.270 |
Why?
|
| Machine Learning | 2 | 2022 | 341 | 0.270 |
Why?
|
| Phenotype | 5 | 2020 | 2544 | 0.270 |
Why?
|
| Sex Factors | 11 | 2017 | 1105 | 0.270 |
Why?
|
| Organ Transplantation | 2 | 2003 | 295 | 0.270 |
Why?
|
| Rabies Vaccines | 2 | 2004 | 7 | 0.270 |
Why?
|
| Crisis Intervention | 1 | 2007 | 13 | 0.270 |
Why?
|
| Minority Groups | 2 | 2023 | 149 | 0.270 |
Why?
|
| Multivariate Analysis | 7 | 2015 | 985 | 0.270 |
Why?
|
| Bites and Stings | 2 | 2004 | 9 | 0.270 |
Why?
|
| Health Policy | 3 | 2025 | 206 | 0.270 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 5 | 2013 | 46 | 0.260 |
Why?
|
| Preoperative Care | 1 | 2010 | 406 | 0.260 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2007 | 34 | 0.260 |
Why?
|
| Patient Dropouts | 1 | 2007 | 31 | 0.260 |
Why?
|
| Program Development | 1 | 2007 | 131 | 0.250 |
Why?
|
| Serotyping | 7 | 2015 | 28 | 0.250 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2022 | 224 | 0.250 |
Why?
|
| Medical Records | 1 | 2007 | 121 | 0.250 |
Why?
|
| Pharmacoepidemiology | 3 | 2011 | 6 | 0.250 |
Why?
|
| Nepal | 6 | 2013 | 17 | 0.240 |
Why?
|
| Graft Rejection | 2 | 2009 | 1120 | 0.240 |
Why?
|
| Drug Utilization | 4 | 2018 | 64 | 0.240 |
Why?
|
| Biomarkers | 5 | 2024 | 1910 | 0.240 |
Why?
|
| Cognition | 2 | 2023 | 627 | 0.240 |
Why?
|
| Influenza Vaccines | 3 | 2018 | 168 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2012 | 367 | 0.230 |
Why?
|
| Genotype | 5 | 2016 | 1866 | 0.230 |
Why?
|
| Patient Selection | 4 | 2016 | 690 | 0.230 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 3 | 2015 | 63 | 0.230 |
Why?
|
| Community Mental Health Services | 5 | 2012 | 21 | 0.230 |
Why?
|
| Sexual Behavior | 4 | 2021 | 328 | 0.230 |
Why?
|
| Disease Outbreaks | 5 | 2015 | 150 | 0.230 |
Why?
|
| Pain Management | 2 | 2018 | 180 | 0.230 |
Why?
|
| Child Behavior Disorders | 3 | 2004 | 76 | 0.220 |
Why?
|
| Risk | 10 | 2019 | 657 | 0.220 |
Why?
|
| Infant, Newborn | 9 | 2018 | 2479 | 0.220 |
Why?
|
| Chiroptera | 2 | 2004 | 56 | 0.220 |
Why?
|
| Patient Health Questionnaire | 1 | 2024 | 3 | 0.220 |
Why?
|
| Propensity Score | 2 | 2019 | 178 | 0.220 |
Why?
|
| Picornaviridae Infections | 2 | 2018 | 7 | 0.210 |
Why?
|
| Likelihood Functions | 4 | 2014 | 256 | 0.210 |
Why?
|
| Buspirone | 1 | 2024 | 1 | 0.210 |
Why?
|
| Age Distribution | 5 | 2017 | 206 | 0.210 |
Why?
|
| Lorazepam | 1 | 2024 | 12 | 0.210 |
Why?
|
| Diazepam | 1 | 2024 | 26 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2011 | 876 | 0.210 |
Why?
|
| Pregnancy | 5 | 2021 | 3147 | 0.210 |
Why?
|
| Pharmacogenetics | 3 | 2025 | 456 | 0.200 |
Why?
|
| Health Education | 2 | 2002 | 105 | 0.200 |
Why?
|
| Hallucinations | 1 | 2023 | 29 | 0.200 |
Why?
|
| Illinois | 4 | 2022 | 520 | 0.200 |
Why?
|
| Rural Population | 9 | 2014 | 170 | 0.200 |
Why?
|
| Thinking | 1 | 2023 | 39 | 0.190 |
Why?
|
| Benztropine | 1 | 2023 | 4 | 0.190 |
Why?
|
| Case-Control Studies | 10 | 2017 | 1931 | 0.190 |
Why?
|
| Citalopram | 2 | 2015 | 21 | 0.190 |
Why?
|
| Patient Portals | 1 | 2023 | 21 | 0.190 |
Why?
|
| Epidemiological Monitoring | 4 | 2017 | 43 | 0.190 |
Why?
|
| Cytokines | 3 | 2019 | 863 | 0.190 |
Why?
|
| Support Vector Machine | 1 | 2022 | 24 | 0.190 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 1546 | 0.190 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 2 | 2015 | 49 | 0.190 |
Why?
|
| Physicians | 4 | 2018 | 682 | 0.190 |
Why?
|
| Self Report | 3 | 2020 | 328 | 0.190 |
Why?
|
| Reagent Kits, Diagnostic | 3 | 2012 | 38 | 0.190 |
Why?
|
| Resource Allocation | 2 | 2019 | 64 | 0.190 |
Why?
|
| Cholecalciferol | 1 | 2022 | 35 | 0.190 |
Why?
|
| Vitamin B 12 | 1 | 2022 | 24 | 0.190 |
Why?
|
| Cognitive Dysfunction | 1 | 2025 | 190 | 0.190 |
Why?
|
| Hemodynamics | 2 | 2016 | 713 | 0.190 |
Why?
|
| Environmental Exposure | 2 | 2003 | 355 | 0.190 |
Why?
|
| Venlafaxine Hydrochloride | 2 | 2012 | 4 | 0.190 |
Why?
|
| Insurance Claim Review | 3 | 2014 | 47 | 0.190 |
Why?
|
| Insect Vectors | 2 | 2015 | 11 | 0.190 |
Why?
|
| Folic Acid | 1 | 2022 | 62 | 0.190 |
Why?
|
| Recreation | 1 | 2002 | 9 | 0.180 |
Why?
|
| Soil | 1 | 2022 | 53 | 0.180 |
Why?
|
| Algorithms | 9 | 2016 | 1953 | 0.180 |
Why?
|
| Population Health | 1 | 2022 | 33 | 0.180 |
Why?
|
| Triage | 1 | 2023 | 131 | 0.180 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2019 | 53 | 0.180 |
Why?
|
| Vitamins | 1 | 2022 | 85 | 0.180 |
Why?
|
| Hepatitis Antibodies | 2 | 2012 | 6 | 0.180 |
Why?
|
| Pain | 3 | 2022 | 414 | 0.180 |
Why?
|
| Dietary Supplements | 1 | 2022 | 131 | 0.180 |
Why?
|
| Software | 2 | 1996 | 670 | 0.180 |
Why?
|
| Neuropsychological Tests | 2 | 2021 | 543 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2015 | 887 | 0.170 |
Why?
|
| Antimanic Agents | 1 | 2001 | 14 | 0.170 |
Why?
|
| Public Health | 1 | 2022 | 153 | 0.170 |
Why?
|
| Heterosexuality | 1 | 2021 | 20 | 0.170 |
Why?
|
| Ethanol | 1 | 2024 | 273 | 0.170 |
Why?
|
| Depression, Postpartum | 1 | 2021 | 12 | 0.170 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 759 | 0.170 |
Why?
|
| Disease Transmission, Infectious | 2 | 2012 | 57 | 0.170 |
Why?
|
| Brain Mapping | 1 | 2004 | 569 | 0.170 |
Why?
|
| Aripiprazole | 1 | 2020 | 6 | 0.170 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2000 | 14 | 0.170 |
Why?
|
| Hand Disinfection | 2 | 2011 | 18 | 0.170 |
Why?
|
| Calibration | 2 | 2018 | 106 | 0.160 |
Why?
|
| Internship and Residency | 3 | 2023 | 1090 | 0.160 |
Why?
|
| Aedes | 2 | 2012 | 13 | 0.160 |
Why?
|
| Nitrous Oxide | 1 | 2021 | 107 | 0.160 |
Why?
|
| Heart Arrest | 2 | 2014 | 311 | 0.160 |
Why?
|
| Heart Failure | 2 | 2025 | 1386 | 0.160 |
Why?
|
| Mentoring | 1 | 2021 | 34 | 0.160 |
Why?
|
| Vitamin D | 1 | 2022 | 272 | 0.160 |
Why?
|
| Attitude of Health Personnel | 2 | 2012 | 660 | 0.160 |
Why?
|
| Psychotropic Drugs | 5 | 2012 | 82 | 0.160 |
Why?
|
| Clinical Deterioration | 1 | 2020 | 28 | 0.160 |
Why?
|
| Lithium | 6 | 1987 | 61 | 0.160 |
Why?
|
| Health Risk Behaviors | 1 | 2020 | 6 | 0.160 |
Why?
|
| Combined Modality Therapy | 8 | 2013 | 1723 | 0.160 |
Why?
|
| Influenza B virus | 2 | 2018 | 33 | 0.160 |
Why?
|
| User-Computer Interface | 1 | 2021 | 189 | 0.160 |
Why?
|
| Schools | 5 | 2013 | 84 | 0.150 |
Why?
|
| Government Regulation | 1 | 2000 | 49 | 0.150 |
Why?
|
| Phylogeny | 7 | 2017 | 1266 | 0.150 |
Why?
|
| Psychopathology | 1 | 2019 | 30 | 0.150 |
Why?
|
| Drug Labeling | 2 | 2011 | 41 | 0.150 |
Why?
|
| Teaching | 1 | 2020 | 141 | 0.150 |
Why?
|
| Perinatal Care | 1 | 2019 | 21 | 0.150 |
Why?
|
| Cross Reactions | 6 | 2015 | 113 | 0.150 |
Why?
|
| Age of Onset | 3 | 2015 | 342 | 0.150 |
Why?
|
| Immunization Schedule | 2 | 2016 | 23 | 0.150 |
Why?
|
| Students | 4 | 2023 | 179 | 0.150 |
Why?
|
| Hospitals | 2 | 2015 | 328 | 0.150 |
Why?
|
| Text Messaging | 1 | 2019 | 35 | 0.150 |
Why?
|
| Patients | 2 | 2010 | 103 | 0.150 |
Why?
|
| Smartphone | 1 | 2019 | 52 | 0.140 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2018 | 5 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 3 | 2018 | 894 | 0.140 |
Why?
|
| Haemophilus Infections | 1 | 2018 | 9 | 0.140 |
Why?
|
| Immunoglobulin G | 4 | 2013 | 464 | 0.140 |
Why?
|
| Self-Assessment | 2 | 2021 | 45 | 0.140 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2018 | 38 | 0.140 |
Why?
|
| Rhinovirus | 3 | 2018 | 29 | 0.140 |
Why?
|
| Latin America | 1 | 2018 | 16 | 0.140 |
Why?
|
| Socioeconomic Factors | 4 | 2014 | 624 | 0.140 |
Why?
|
| Klebsiella Infections | 1 | 2018 | 32 | 0.140 |
Why?
|
| Alcoholism | 7 | 1993 | 188 | 0.140 |
Why?
|
| Wilderness Medicine | 1 | 2018 | 1 | 0.140 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 183 | 0.140 |
Why?
|
| Culicidae | 2 | 2015 | 8 | 0.140 |
Why?
|
| Psychophysiologic Disorders | 1 | 1998 | 5 | 0.140 |
Why?
|
| Fever | 3 | 2018 | 122 | 0.140 |
Why?
|
| Animals | 16 | 2015 | 28155 | 0.140 |
Why?
|
| Mobile Applications | 1 | 2019 | 78 | 0.140 |
Why?
|
| House Calls | 1 | 1997 | 13 | 0.140 |
Why?
|
| Somatoform Disorders | 1 | 1998 | 31 | 0.140 |
Why?
|
| Cognition Disorders | 2 | 2018 | 236 | 0.130 |
Why?
|
| Patient Compliance | 3 | 2017 | 237 | 0.130 |
Why?
|
| Survival Analysis | 5 | 2019 | 1524 | 0.130 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 65 | 0.130 |
Why?
|
| Medial Forebrain Bundle | 1 | 2017 | 1 | 0.130 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2017 | 3 | 0.130 |
Why?
|
| Health Resources | 1 | 2018 | 80 | 0.130 |
Why?
|
| Analgesia | 1 | 2018 | 64 | 0.130 |
Why?
|
| Drug Industry | 1 | 1998 | 56 | 0.130 |
Why?
|
| Family Characteristics | 3 | 2014 | 52 | 0.130 |
Why?
|
| Fatigue | 1 | 2018 | 181 | 0.130 |
Why?
|
| Attitude to Health | 2 | 1998 | 217 | 0.130 |
Why?
|
| Proportional Hazards Models | 4 | 2024 | 889 | 0.130 |
Why?
|
| Hospital Rapid Response Team | 2 | 2014 | 28 | 0.130 |
Why?
|
| Clinical Coding | 1 | 2017 | 23 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2016 | 1229 | 0.130 |
Why?
|
| Population Density | 1 | 2017 | 70 | 0.120 |
Why?
|
| Photoplethysmography | 1 | 2016 | 3 | 0.120 |
Why?
|
| Decision Trees | 1 | 2016 | 64 | 0.120 |
Why?
|
| Antidepressive Agents, Tricyclic | 3 | 2007 | 20 | 0.120 |
Why?
|
| Immunologic Memory | 2 | 2019 | 184 | 0.120 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 2 | 2013 | 8 | 0.120 |
Why?
|
| Seroepidemiologic Studies | 5 | 2015 | 56 | 0.120 |
Why?
|
| Patient Transfer | 2 | 2014 | 108 | 0.120 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2014 | 38 | 0.120 |
Why?
|
| Program Evaluation | 3 | 2020 | 315 | 0.120 |
Why?
|
| Markov Chains | 2 | 2014 | 135 | 0.120 |
Why?
|
| HIV Infections | 3 | 2015 | 961 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2016 | 66 | 0.120 |
Why?
|
| Diffusion of Innovation | 2 | 2015 | 77 | 0.120 |
Why?
|
| Drug Costs | 1 | 1996 | 66 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 1914 | 0.120 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 286 | 0.120 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2015 | 13 | 0.120 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2015 | 14 | 0.120 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 109 | 0.110 |
Why?
|
| Pharynx | 2 | 2018 | 44 | 0.110 |
Why?
|
| Vagus Nerve | 1 | 2015 | 45 | 0.110 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 124 | 0.110 |
Why?
|
| Dexamethasone | 3 | 1987 | 312 | 0.110 |
Why?
|
| Seizures | 1 | 2018 | 311 | 0.110 |
Why?
|
| Blood Transfusion | 1 | 2016 | 175 | 0.110 |
Why?
|
| Unemployment | 2 | 2012 | 11 | 0.110 |
Why?
|
| Genes, MHC Class I | 1 | 2015 | 46 | 0.110 |
Why?
|
| Nerve Block | 1 | 2015 | 51 | 0.110 |
Why?
|
| Chicago | 4 | 2022 | 1464 | 0.110 |
Why?
|
| Health Services Research | 1 | 2015 | 142 | 0.110 |
Why?
|
| Hemagglutination Inhibition Tests | 4 | 2015 | 42 | 0.110 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2014 | 33 | 0.110 |
Why?
|
| Probability | 3 | 2009 | 355 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 74 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 356 | 0.100 |
Why?
|
| Autism Spectrum Disorder | 1 | 2015 | 87 | 0.100 |
Why?
|
| Hospital Administration | 1 | 2014 | 24 | 0.100 |
Why?
|
| Prognosis | 5 | 2021 | 3911 | 0.100 |
Why?
|
| Telemedicine | 1 | 2017 | 225 | 0.100 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2013 | 4 | 0.100 |
Why?
|
| HLA-B Antigens | 1 | 2014 | 27 | 0.100 |
Why?
|
| Urban Population | 2 | 2012 | 234 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2014 | 59 | 0.100 |
Why?
|
| Varenicline | 1 | 2013 | 16 | 0.100 |
Why?
|
| Psychomotor Agitation | 1 | 2013 | 30 | 0.100 |
Why?
|
| Influenza A virus | 2 | 2011 | 172 | 0.100 |
Why?
|
| Rabies virus | 2 | 2004 | 6 | 0.100 |
Why?
|
| Bupropion | 1 | 2013 | 21 | 0.100 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 66 | 0.100 |
Why?
|
| Immunity, Humoral | 1 | 2014 | 74 | 0.100 |
Why?
|
| Myocardial Contraction | 1 | 2014 | 188 | 0.100 |
Why?
|
| Reassortant Viruses | 1 | 2013 | 23 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2016 | 283 | 0.100 |
Why?
|
| Weight Loss | 1 | 2015 | 234 | 0.100 |
Why?
|
| Diabetes, Gestational | 1 | 2014 | 49 | 0.100 |
Why?
|
| Nausea | 1 | 2013 | 93 | 0.100 |
Why?
|
| Confidence Intervals | 2 | 2010 | 217 | 0.100 |
Why?
|
| Saccades | 2 | 2025 | 75 | 0.100 |
Why?
|
| Swine Diseases | 1 | 2013 | 15 | 0.100 |
Why?
|
| Computing Methodologies | 1 | 2013 | 8 | 0.100 |
Why?
|
| Cross Protection | 1 | 2013 | 11 | 0.100 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 191 | 0.100 |
Why?
|
| Smoking | 2 | 2017 | 648 | 0.100 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2014 | 75 | 0.100 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2014 | 96 | 0.100 |
Why?
|
| Survival Rate | 2 | 2025 | 1948 | 0.100 |
Why?
|
| Models, Immunological | 1 | 2013 | 84 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2015 | 257 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 3 | 2013 | 893 | 0.100 |
Why?
|
| Length of Stay | 3 | 2008 | 828 | 0.100 |
Why?
|
| Tranquilizing Agents | 1 | 2012 | 6 | 0.100 |
Why?
|
| Double-Blind Method | 5 | 2021 | 1729 | 0.100 |
Why?
|
| Coronary Disease | 1 | 2014 | 223 | 0.100 |
Why?
|
| Inpatients | 2 | 2014 | 345 | 0.100 |
Why?
|
| Health Plan Implementation | 1 | 2013 | 63 | 0.090 |
Why?
|
| Emigration and Immigration | 1 | 2013 | 49 | 0.090 |
Why?
|
| Random Allocation | 4 | 1997 | 307 | 0.090 |
Why?
|
| Inflammation | 1 | 2019 | 1050 | 0.090 |
Why?
|
| Off-Label Use | 1 | 2012 | 16 | 0.090 |
Why?
|
| Bhutan | 1 | 2012 | 3 | 0.090 |
Why?
|
| Molecular Epidemiology | 2 | 2013 | 57 | 0.090 |
Why?
|
| Vaccines, Attenuated | 3 | 2019 | 52 | 0.090 |
Why?
|
| Marketing | 1 | 2012 | 23 | 0.090 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 181 | 0.090 |
Why?
|
| Health Promotion | 2 | 2013 | 170 | 0.090 |
Why?
|
| Endemic Diseases | 2 | 2019 | 5 | 0.090 |
Why?
|
| Factor Analysis, Statistical | 2 | 2008 | 115 | 0.090 |
Why?
|
| Obesity, Morbid | 1 | 2015 | 244 | 0.090 |
Why?
|
| Organizational Culture | 1 | 2012 | 33 | 0.090 |
Why?
|
| New York City | 1 | 2012 | 69 | 0.090 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 258 | 0.090 |
Why?
|
| Pharmacovigilance | 1 | 2012 | 3 | 0.090 |
Why?
|
| Adrenergic Agents | 1 | 2012 | 6 | 0.090 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 99 | 0.090 |
Why?
|
| Molecular Sequence Data | 3 | 2013 | 2910 | 0.090 |
Why?
|
| Homosexuality, Male | 1 | 2015 | 332 | 0.090 |
Why?
|
| Environment | 1 | 2014 | 230 | 0.090 |
Why?
|
| Viremia | 1 | 2012 | 51 | 0.090 |
Why?
|
| Stroke Volume | 1 | 2014 | 438 | 0.090 |
Why?
|
| Child Health Services | 2 | 2004 | 47 | 0.090 |
Why?
|
| Morbidity | 2 | 2022 | 162 | 0.090 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 630 | 0.090 |
Why?
|
| Poultry Diseases | 1 | 2011 | 13 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 208 | 0.090 |
Why?
|
| Hantavirus Infections | 1 | 2011 | 2 | 0.090 |
Why?
|
| Shrews | 1 | 2011 | 5 | 0.090 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2011 | 15 | 0.090 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 78 | 0.090 |
Why?
|
| Occupational Exposure | 1 | 2012 | 87 | 0.090 |
Why?
|
| Phenylcarbamates | 1 | 2011 | 5 | 0.090 |
Why?
|
| Tosyl Compounds | 1 | 2011 | 13 | 0.090 |
Why?
|
| Health Services Accessibility | 2 | 2006 | 481 | 0.090 |
Why?
|
| Cyclopropanes | 1 | 2011 | 26 | 0.090 |
Why?
|
| Aging | 1 | 2016 | 727 | 0.090 |
Why?
|
| Norepinephrine | 3 | 1988 | 169 | 0.090 |
Why?
|
| Health Care Surveys | 2 | 2012 | 285 | 0.090 |
Why?
|
| Hydroxyindoleacetic Acid | 3 | 1990 | 26 | 0.090 |
Why?
|
| Acetates | 1 | 2011 | 60 | 0.090 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2011 | 56 | 0.090 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2012 | 93 | 0.080 |
Why?
|
| Panic Disorder | 2 | 2008 | 21 | 0.080 |
Why?
|
| Pollen | 1 | 2011 | 84 | 0.080 |
Why?
|
| Sulfides | 1 | 2011 | 68 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2012 | 119 | 0.080 |
Why?
|
| Antibodies, Bacterial | 1 | 2011 | 103 | 0.080 |
Why?
|
| Vital Signs | 2 | 2022 | 36 | 0.080 |
Why?
|
| Hydroxyurea | 1 | 2011 | 231 | 0.080 |
Why?
|
| Methoxyhydroxyphenylglycol | 4 | 1988 | 18 | 0.080 |
Why?
|
| Conduct Disorder | 1 | 2011 | 65 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2012 | 314 | 0.080 |
Why?
|
| Smoking Prevention | 3 | 1996 | 46 | 0.080 |
Why?
|
| Quinolines | 1 | 2011 | 85 | 0.080 |
Why?
|
| Allergens | 1 | 2011 | 189 | 0.080 |
Why?
|
| Environmental Microbiology | 1 | 2010 | 22 | 0.080 |
Why?
|
| Animal Structures | 1 | 2010 | 27 | 0.080 |
Why?
|
| Masks | 1 | 2011 | 31 | 0.080 |
Why?
|
| Acute Disease | 3 | 2018 | 841 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2014 | 454 | 0.080 |
Why?
|
| Cities | 1 | 2010 | 57 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 1985 | 0.080 |
Why?
|
| Seasons | 1 | 2011 | 240 | 0.080 |
Why?
|
| Transcriptome | 1 | 2016 | 762 | 0.080 |
Why?
|
| Virology | 1 | 2010 | 13 | 0.080 |
Why?
|
| Analysis of Variance | 4 | 2012 | 884 | 0.080 |
Why?
|
| Models, Biological | 3 | 2014 | 1768 | 0.080 |
Why?
|
| Data Collection | 3 | 2015 | 370 | 0.080 |
Why?
|
| Antibody-Dependent Enhancement | 1 | 2009 | 2 | 0.080 |
Why?
|
| Aggression | 1 | 2013 | 330 | 0.080 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2010 | 98 | 0.080 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2010 | 39 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 289 | 0.080 |
Why?
|
| Medication Errors | 1 | 2010 | 36 | 0.080 |
Why?
|
| Nose | 1 | 2010 | 95 | 0.080 |
Why?
|
| Registries | 2 | 2019 | 990 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2014 | 660 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 306 | 0.080 |
Why?
|
| Indoles | 1 | 2011 | 303 | 0.080 |
Why?
|
| Speech | 1 | 2010 | 90 | 0.070 |
Why?
|
| Debrisoquin | 1 | 1989 | 1 | 0.070 |
Why?
|
| Levorphanol | 1 | 1989 | 2 | 0.070 |
Why?
|
| Imipramine | 2 | 1995 | 16 | 0.070 |
Why?
|
| Infection Control | 1 | 2010 | 130 | 0.070 |
Why?
|
| Dextromethorphan | 1 | 1989 | 11 | 0.070 |
Why?
|
| Observer Variation | 1 | 2010 | 570 | 0.070 |
Why?
|
| Postpartum Period | 2 | 2021 | 159 | 0.070 |
Why?
|
| Isoquinolines | 1 | 1989 | 57 | 0.070 |
Why?
|
| Prostatectomy | 2 | 2011 | 478 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2011 | 331 | 0.070 |
Why?
|
| Viral Envelope Proteins | 3 | 2015 | 81 | 0.070 |
Why?
|
| Personality Assessment | 4 | 2010 | 99 | 0.070 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 337 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 2011 | 1775 | 0.070 |
Why?
|
| Haemophilus influenzae type b | 2 | 2018 | 3 | 0.070 |
Why?
|
| Placebos | 5 | 2014 | 206 | 0.070 |
Why?
|
| Electroencephalography | 2 | 2025 | 797 | 0.070 |
Why?
|
| Epilepsy | 1 | 2013 | 434 | 0.070 |
Why?
|
| Clinical Trials as Topic | 6 | 2011 | 1103 | 0.070 |
Why?
|
| Adolescent Health Services | 1 | 2008 | 13 | 0.070 |
Why?
|
| Streptococcus pneumoniae | 2 | 2018 | 51 | 0.070 |
Why?
|
| ABO Blood-Group System | 1 | 2008 | 59 | 0.070 |
Why?
|
| Agoraphobia | 1 | 2008 | 2 | 0.070 |
Why?
|
| Phobic Disorders | 1 | 2008 | 13 | 0.070 |
Why?
|
| Histocompatibility Testing | 1 | 2008 | 140 | 0.070 |
Why?
|
| Schizophrenic Psychology | 3 | 1993 | 141 | 0.070 |
Why?
|
| Linear Models | 2 | 2012 | 413 | 0.070 |
Why?
|
| Leptospirosis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2022 | 917 | 0.070 |
Why?
|
| European Union | 1 | 2007 | 8 | 0.070 |
Why?
|
| Utilization Review | 2 | 2017 | 23 | 0.070 |
Why?
|
| Netherlands | 1 | 2007 | 25 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 111 | 0.070 |
Why?
|
| Monoamine Oxidase | 2 | 1984 | 24 | 0.070 |
Why?
|
| Epidemiologic Research Design | 1 | 2007 | 23 | 0.070 |
Why?
|
| Prostate | 1 | 2011 | 416 | 0.070 |
Why?
|
| Psychology | 1 | 2007 | 26 | 0.070 |
Why?
|
| Homovanillic Acid | 2 | 1988 | 35 | 0.070 |
Why?
|
| Juvenile Delinquency | 1 | 2007 | 29 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2008 | 158 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 2495 | 0.060 |
Why?
|
| Pleural Effusion | 1 | 2007 | 42 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 701 | 0.060 |
Why?
|
| Diagnosis-Related Groups | 1 | 2006 | 21 | 0.060 |
Why?
|
| Swine | 3 | 2013 | 588 | 0.060 |
Why?
|
| Glycols | 1 | 1986 | 8 | 0.060 |
Why?
|
| Global Health | 1 | 2008 | 208 | 0.060 |
Why?
|
| Specialization | 2 | 1997 | 67 | 0.060 |
Why?
|
| Spatio-Temporal Analysis | 2 | 2017 | 26 | 0.060 |
Why?
|
| Income | 1 | 2006 | 87 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2023 | 822 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2022 | 624 | 0.060 |
Why?
|
| Disease | 2 | 1983 | 92 | 0.060 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2008 | 160 | 0.060 |
Why?
|
| Early Diagnosis | 2 | 2018 | 135 | 0.060 |
Why?
|
| Bias | 2 | 2006 | 137 | 0.060 |
Why?
|
| Certification | 2 | 2023 | 60 | 0.060 |
Why?
|
| Orthomyxoviridae | 2 | 2018 | 46 | 0.060 |
Why?
|
| Leukocyte Count | 2 | 2019 | 210 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2004 | 1053 | 0.050 |
Why?
|
| Disease Reservoirs | 1 | 2004 | 23 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2010 | 878 | 0.050 |
Why?
|
| Child Welfare | 1 | 2004 | 44 | 0.050 |
Why?
|
| Evoked Potentials | 1 | 2025 | 194 | 0.050 |
Why?
|
| Travel | 1 | 2004 | 73 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 1275 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2004 | 122 | 0.050 |
Why?
|
| Asthma | 1 | 2012 | 1039 | 0.050 |
Why?
|
| Pharmacogenomic Testing | 1 | 2025 | 107 | 0.050 |
Why?
|
| Prejudice | 1 | 2004 | 49 | 0.050 |
Why?
|
| Malpractice | 2 | 1995 | 47 | 0.050 |
Why?
|
| Medicare | 2 | 2017 | 455 | 0.050 |
Why?
|
| Dogs | 1 | 2004 | 634 | 0.050 |
Why?
|
| Geography | 2 | 2016 | 240 | 0.050 |
Why?
|
| Child Abuse | 1 | 2004 | 93 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2025 | 142 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 4 | 1999 | 242 | 0.050 |
Why?
|
| Quality of Health Care | 2 | 2019 | 382 | 0.050 |
Why?
|
| Persian Gulf Syndrome | 1 | 2003 | 5 | 0.050 |
Why?
|
| Warfare | 1 | 2003 | 12 | 0.050 |
Why?
|
| Neutralization Tests | 2 | 2015 | 72 | 0.050 |
Why?
|
| Licensure, Medical | 1 | 2023 | 21 | 0.050 |
Why?
|
| Appointments and Schedules | 1 | 2023 | 57 | 0.050 |
Why?
|
| Awareness | 2 | 2021 | 89 | 0.050 |
Why?
|
| Causality | 1 | 2003 | 82 | 0.050 |
Why?
|
| Fissure in Ano | 1 | 2002 | 3 | 0.050 |
Why?
|
| Social Support | 2 | 2019 | 233 | 0.050 |
Why?
|
| Influenza in Birds | 2 | 2013 | 29 | 0.050 |
Why?
|
| Nitroglycerin | 1 | 2002 | 24 | 0.050 |
Why?
|
| Motor Vehicles | 1 | 2022 | 19 | 0.050 |
Why?
|
| Perioperative Care | 1 | 2024 | 188 | 0.050 |
Why?
|
| Laos | 2 | 2015 | 4 | 0.050 |
Why?
|
| Japan | 2 | 2007 | 299 | 0.050 |
Why?
|
| Endophenotypes | 1 | 2022 | 19 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2002 | 133 | 0.040 |
Why?
|
| Japanese Encephalitis Vaccines | 2 | 2013 | 2 | 0.040 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2022 | 39 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2022 | 81 | 0.040 |
Why?
|
| Blood Platelets | 3 | 2010 | 150 | 0.040 |
Why?
|
| Skin Pigmentation | 1 | 2021 | 36 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2022 | 117 | 0.040 |
Why?
|
| Case Management | 1 | 2021 | 29 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2003 | 243 | 0.040 |
Why?
|
| National Institute of Mental Health (U.S.) | 2 | 2007 | 22 | 0.040 |
Why?
|
| Policy | 1 | 2021 | 41 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2004 | 408 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 194 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2023 | 238 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 829 | 0.040 |
Why?
|
| Occupational Stress | 1 | 2020 | 5 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2001 | 154 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 116 | 0.040 |
Why?
|
| Injections | 1 | 2020 | 124 | 0.040 |
Why?
|
| Sampling Studies | 2 | 1997 | 75 | 0.040 |
Why?
|
| Child, Hospitalized | 1 | 2020 | 41 | 0.040 |
Why?
|
| World Health Organization | 2 | 2010 | 121 | 0.040 |
Why?
|
| Immunoassay | 2 | 2010 | 99 | 0.040 |
Why?
|
| Health Planning | 1 | 1999 | 16 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2019 | 38 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2021 | 157 | 0.040 |
Why?
|
| Triazolam | 1 | 1999 | 5 | 0.040 |
Why?
|
| Hydrocortisone | 3 | 1987 | 296 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 33 | 0.040 |
Why?
|
| Kinetics | 2 | 2015 | 1492 | 0.040 |
Why?
|
| Emotions | 1 | 1983 | 372 | 0.040 |
Why?
|
| Manuals as Topic | 1 | 1998 | 9 | 0.040 |
Why?
|
| Adjustment Disorders | 1 | 1998 | 6 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2022 | 497 | 0.040 |
Why?
|
| Affective Symptoms | 2 | 2004 | 56 | 0.040 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2018 | 16 | 0.030 |
Why?
|
| Klebsiella pneumoniae | 1 | 2018 | 35 | 0.030 |
Why?
|
| Disease Progression | 2 | 2016 | 1531 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 2018 | 91 | 0.030 |
Why?
|
| Serotonin | 2 | 2010 | 209 | 0.030 |
Why?
|
| Internal-External Control | 1 | 1998 | 45 | 0.030 |
Why?
|
| Television | 1 | 1997 | 28 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 220 | 0.030 |
Why?
|
| Hypnotics and Sedatives | 1 | 1999 | 137 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2018 | 64 | 0.030 |
Why?
|
| Calcinosis | 1 | 1999 | 222 | 0.030 |
Why?
|
| Professional Practice | 1 | 1997 | 43 | 0.030 |
Why?
|
| Reference Values | 3 | 2009 | 608 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2018 | 232 | 0.030 |
Why?
|
| Conflict of Interest | 1 | 1998 | 70 | 0.030 |
Why?
|
| Platelet Count | 2 | 2010 | 90 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 1999 | 178 | 0.030 |
Why?
|
| Mosquito Vectors | 1 | 2017 | 8 | 0.030 |
Why?
|
| Intubation, Gastrointestinal | 1 | 1997 | 30 | 0.030 |
Why?
|
| Breath Tests | 2 | 1988 | 58 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2000 | 336 | 0.030 |
Why?
|
| Pneumoconiosis | 1 | 1996 | 5 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 756 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 69 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 68 | 0.030 |
Why?
|
| Medicine | 1 | 1997 | 95 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2019 | 454 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 1997 | 104 | 0.030 |
Why?
|
| Health Behavior | 1 | 1997 | 182 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 2016 | 37 | 0.030 |
Why?
|
| Patient Admission | 1 | 1996 | 119 | 0.030 |
Why?
|
| Injections, Intradermal | 1 | 2015 | 19 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 484 | 0.030 |
Why?
|
| Asia, Southeastern | 1 | 2015 | 18 | 0.030 |
Why?
|
| Serogroup | 1 | 2015 | 11 | 0.030 |
Why?
|
| Vaccines, Inactivated | 1 | 2015 | 32 | 0.030 |
Why?
|
| Insurance, Liability | 1 | 1995 | 9 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1997 | 160 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2015 | 63 | 0.030 |
Why?
|
| Immune Sera | 1 | 2015 | 48 | 0.030 |
Why?
|
| Legislation, Medical | 1 | 1995 | 9 | 0.030 |
Why?
|
| Hospitals, Military | 1 | 2015 | 3 | 0.030 |
Why?
|
| Video Recording | 1 | 1997 | 212 | 0.030 |
Why?
|
| Heartburn | 1 | 2015 | 10 | 0.030 |
Why?
|
| Tropical Climate | 1 | 2015 | 35 | 0.030 |
Why?
|
| Risk Management | 1 | 1995 | 38 | 0.030 |
Why?
|
| Dyspepsia | 1 | 2015 | 9 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 284 | 0.030 |
Why?
|
| Psychology, Adolescent | 1 | 2015 | 26 | 0.030 |
Why?
|
| Climate | 1 | 2015 | 61 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 255 | 0.030 |
Why?
|
| Electrodes | 1 | 2015 | 97 | 0.030 |
Why?
|
| Pediatrics | 1 | 1999 | 385 | 0.030 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2014 | 4 | 0.030 |
Why?
|
| Geography, Medical | 1 | 2014 | 2 | 0.030 |
Why?
|
| Mathematics | 1 | 1994 | 180 | 0.030 |
Why?
|
| Spatial Analysis | 1 | 2014 | 11 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 1 | 2014 | 30 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 242 | 0.030 |
Why?
|
| Specialties, Surgical | 1 | 1995 | 75 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 1997 | 373 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 124 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 1999 | 375 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2014 | 19 | 0.030 |
Why?
|
| Critical Care | 2 | 2014 | 444 | 0.030 |
Why?
|
| Alcohol Drinking | 2 | 2007 | 283 | 0.030 |
Why?
|
| Erythrocytes | 3 | 1984 | 239 | 0.030 |
Why?
|
| Pursuit, Smooth | 2 | 1984 | 31 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2015 | 143 | 0.030 |
Why?
|
| Basic Reproduction Number | 1 | 2013 | 6 | 0.030 |
Why?
|
| DNA Primers | 1 | 2014 | 531 | 0.030 |
Why?
|
| Eye Movements | 2 | 1985 | 119 | 0.030 |
Why?
|
| Hawaii | 1 | 2013 | 26 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2015 | 347 | 0.020 |
Why?
|
| Research | 2 | 1985 | 251 | 0.020 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2013 | 13 | 0.020 |
Why?
|
| Hospitals, Public | 1 | 1993 | 15 | 0.020 |
Why?
|
| Cell Phone | 1 | 2013 | 39 | 0.020 |
Why?
|
| Economic Recession | 1 | 2012 | 5 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2014 | 281 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2012 | 49 | 0.020 |
Why?
|
| Health Surveys | 1 | 2013 | 241 | 0.020 |
Why?
|
| Survivors | 1 | 2014 | 204 | 0.020 |
Why?
|
| Clinical Medicine | 1 | 1992 | 30 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 262 | 0.020 |
Why?
|
| Receptors, Leukotriene | 1 | 2012 | 10 | 0.020 |
Why?
|
| Temperance | 1 | 1992 | 6 | 0.020 |
Why?
|
| Forecasting | 1 | 2013 | 293 | 0.020 |
Why?
|
| Housing | 1 | 2012 | 50 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2014 | 448 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2014 | 476 | 0.020 |
Why?
|
| Death Certificates | 1 | 2011 | 11 | 0.020 |
Why?
|
| Poultry | 1 | 2011 | 22 | 0.020 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2011 | 8 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 811 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2011 | 42 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2011 | 69 | 0.020 |
Why?
|
| Cerebral Ventricles | 1 | 1991 | 66 | 0.020 |
Why?
|
| Birds | 1 | 2013 | 172 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 43 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2011 | 140 | 0.020 |
Why?
|
| Feces | 1 | 2013 | 360 | 0.020 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2011 | 81 | 0.020 |
Why?
|
| Serum | 1 | 2011 | 25 | 0.020 |
Why?
|
| Afghanistan | 1 | 2010 | 3 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2011 | 51 | 0.020 |
Why?
|
| Viral Plaque Assay | 1 | 2010 | 17 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 797 | 0.020 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2011 | 179 | 0.020 |
Why?
|
| Hematocrit | 1 | 2010 | 66 | 0.020 |
Why?
|
| Nurse Practitioners | 1 | 2010 | 33 | 0.020 |
Why?
|
| Humidity | 1 | 2010 | 94 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 71 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 293 | 0.020 |
Why?
|
| Philippines | 1 | 2010 | 22 | 0.020 |
Why?
|
| Irritable Mood | 1 | 2010 | 10 | 0.020 |
Why?
|
| Normetanephrine | 2 | 1988 | 4 | 0.020 |
Why?
|
| Indonesia | 1 | 2010 | 12 | 0.020 |
Why?
|
| Lithium Carbonate | 2 | 1987 | 7 | 0.020 |
Why?
|
| Curriculum | 1 | 1994 | 594 | 0.020 |
Why?
|
| Pharmacists | 1 | 2010 | 36 | 0.020 |
Why?
|
| Hand | 1 | 2010 | 143 | 0.020 |
Why?
|
| Nurses | 1 | 2010 | 42 | 0.020 |
Why?
|
| Reference Standards | 1 | 2010 | 146 | 0.020 |
Why?
|
| Hearing | 1 | 2010 | 62 | 0.020 |
Why?
|
| Nasal Mucosa | 1 | 2010 | 193 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2010 | 109 | 0.020 |
Why?
|
| Leukocytes | 1 | 2010 | 210 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2015 | 878 | 0.020 |
Why?
|
| Behavioral Symptoms | 1 | 2009 | 15 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1999 | 2585 | 0.020 |
Why?
|
| Temperature | 1 | 2010 | 424 | 0.020 |
Why?
|
| Public Health Practice | 1 | 2009 | 11 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2010 | 128 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 157 | 0.020 |
Why?
|
| Financing, Government | 1 | 2009 | 25 | 0.020 |
Why?
|
| Introns | 1 | 2010 | 300 | 0.020 |
Why?
|
| Auditory Perception | 1 | 2010 | 104 | 0.020 |
Why?
|
| Biogenic Amines | 1 | 1988 | 2 | 0.020 |
Why?
|
| Patient Readmission | 1 | 1993 | 412 | 0.020 |
Why?
|
| Capsid Proteins | 1 | 2008 | 26 | 0.020 |
Why?
|
| South Africa | 1 | 2008 | 61 | 0.020 |
Why?
|
| Family Relations | 1 | 2008 | 37 | 0.020 |
Why?
|
| Stress, Psychological | 2 | 2003 | 342 | 0.020 |
Why?
|
| Preventive Health Services | 1 | 2008 | 38 | 0.020 |
Why?
|
| Irritants | 1 | 1988 | 4 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 1721 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 135 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1989 | 410 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2002 | 960 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 314 | 0.020 |
Why?
|
| Serologic Tests | 1 | 2007 | 41 | 0.020 |
Why?
|
| Eye Diseases | 1 | 1988 | 58 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 302 | 0.020 |
Why?
|
| Gallbladder | 1 | 2007 | 32 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 2484 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 96 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 335 | 0.020 |
Why?
|
| Ascites | 1 | 2007 | 54 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2008 | 248 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 1 | 1987 | 64 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1987 | 80 | 0.020 |
Why?
|
| Vanilmandelic Acid | 1 | 1986 | 4 | 0.020 |
Why?
|
| Neurons | 1 | 2014 | 1582 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2465 | 0.010 |
Why?
|
| Computers | 3 | 1994 | 102 | 0.010 |
Why?
|
| ROC Curve | 1 | 2007 | 775 | 0.010 |
Why?
|
| Schizophrenic Language | 1 | 1985 | 2 | 0.010 |
Why?
|
| Child, Abandoned | 1 | 2004 | 1 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2007 | 327 | 0.010 |
Why?
|
| Social Adjustment | 1 | 1985 | 47 | 0.010 |
Why?
|
| Foster Home Care | 1 | 2004 | 8 | 0.010 |
Why?
|
| Verbal Behavior | 1 | 1985 | 33 | 0.010 |
Why?
|
| Electroconvulsive Therapy | 1 | 1985 | 26 | 0.010 |
Why?
|
| Recurrence | 3 | 1996 | 1190 | 0.010 |
Why?
|
| Poverty Areas | 1 | 2004 | 37 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2007 | 702 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 1988 | 2365 | 0.010 |
Why?
|
| Osteogenesis Imperfecta | 1 | 1984 | 3 | 0.010 |
Why?
|
| Arousal | 1 | 1985 | 171 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 557 | 0.010 |
Why?
|
| Blood Proteins | 1 | 1984 | 145 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2003 | 60 | 0.010 |
Why?
|
| Ointments | 1 | 2002 | 10 | 0.010 |
Why?
|
| Affective Disorders, Psychotic | 1 | 1982 | 16 | 0.010 |
Why?
|
| Play and Playthings | 1 | 2001 | 7 | 0.010 |
Why?
|
| Students, Medical | 1 | 1987 | 435 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2004 | 375 | 0.010 |
Why?
|
| Ion Channels | 1 | 1982 | 256 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2001 | 170 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2002 | 373 | 0.010 |
Why?
|
| Specialty Boards | 1 | 2000 | 22 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 1988 | 1660 | 0.010 |
Why?
|
| Mother-Child Relations | 1 | 1999 | 31 | 0.010 |
Why?
|
| Life Change Events | 1 | 1999 | 46 | 0.010 |
Why?
|
| Professional Staff Committees | 1 | 1999 | 6 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1999 | 109 | 0.010 |
Why?
|
| Mental Health Services | 1 | 1999 | 77 | 0.010 |
Why?
|
| Family | 1 | 1999 | 324 | 0.010 |
Why?
|
| Patients' Rooms | 1 | 1997 | 14 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 1988 | 41 | 0.010 |
Why?
|
| Oregon | 1 | 1995 | 23 | 0.010 |
Why?
|
| Calcium | 1 | 1999 | 1176 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1995 | 210 | 0.010 |
Why?
|
| Critical Illness | 1 | 1997 | 343 | 0.010 |
Why?
|
| Marital Status | 1 | 1993 | 43 | 0.010 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 1992 | 25 | 0.010 |
Why?
|
| Normal Distribution | 1 | 1991 | 38 | 0.010 |
Why?
|
| Metanephrine | 1 | 1988 | 6 | 0.000 |
Why?
|
| Epinephrine | 1 | 1988 | 92 | 0.000 |
Why?
|
| Rabbits | 1 | 1988 | 618 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1988 | 285 | 0.000 |
Why?
|
| Periodicals as Topic | 1 | 1987 | 168 | 0.000 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1985 | 6 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1985 | 193 | 0.000 |
Why?
|
| Erythrocyte Membrane | 1 | 1982 | 61 | 0.000 |
Why?
|
| Sodium | 1 | 1982 | 329 | 0.000 |
Why?
|
| Chromosome Mapping | 1 | 1983 | 1052 | 0.000 |
Why?
|
| Alleles | 1 | 1983 | 1139 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1983 | 826 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1985 | 1077 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1985 | 1173 | 0.000 |
Why?
|